PACB - Pacific Biosciences of California, Inc.
| Previous Close | 5.14 |
| Open | 5.13 |
| Bid | 5.14 x 1300 |
| Ask | 5.15 x 800 |
| Day's Range | 5.06 - 5.29 |
| 52 Week Range | 2.02 - 5.58 |
| Volume | 531,925 |
| Avg. Volume | 1,085,709 |
| Market Cap | 748.281M |
| Beta | 3.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.73 |
| Earnings Date | Oct 31, 2018 - Nov 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.72 |
- Zacks•4 days ago
Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel
Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.
- Zacks•4 days ago
Pacific Biosciences (PACB) Jumps: Stock Rises 5.4%
Pacific Biosciences (PACB) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.
Market Realist•5 days agoWhy Is Pacific Biosciences Stock Up ~6.2% Today?
Today, Pacific Biosciences of California (PACB) is trading at $5.16 per share, up ~6.17% from yesterday’s close of $4.86. On September 12, Pacific Biosciences stock closed at $4.86, a 6.46% increase from its September 11 closing price of $4.57. Its September 12 stock price represented an ~141.0% rise from its 52-week low of $2.02 on April 2. Its stock price hit its 52-week high of $5.58 on October 3, 2017.
- GlobeNewswire•5 days ago
Large-Scale Global Genome Projects Choose PacBio Sequencing to Help Decode Life
When creating a genomic ark of creatures great and small, scientists across the globe are turning to the comprehensive coverage and quality of long-read sequencing technology from Pacific Biosciences (PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes. Today, the Vertebrate Genomes Project (VGP), an international consortium of more than 150 scientists from 50 academic, industry and government institutions in 12 countries, released the first 15 of an anticipated 66,000 high-quality reference genomes that will eventually include all vertebrate species on Earth. The VGP is one of many large-scale international projects that have chosen PacBio® Single Molecule, Real-Time (SMRT®) Sequencing to generate some of the most complete genomes to date for thousands of plant, animal, fungal and bacterial species.
- Zacks•6 days ago
Is the Options Market Predicting a Spike in Pacific Biosciences (PACB) Stock?
Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.
- GlobeNewswire•7 days ago
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
Pacific Biosciences intends to use the net proceeds from the offering for general corporate purposes, including capital expenditures and working capital. Pacific Biosciences may also use a portion of the net proceeds from the offering to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property, although it has no present commitments or agreements to do so. A shelf registration statement relating to the shares of common stock was previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective on August 18, 2017. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC on September 10, 2018.
- Motley Fool•7 days ago
Why Pacific Biosciences Fell By 10.6% Earlier Today
The gene sequencing company plans to tap investors for more cash.
- GlobeNewswire•8 days ago
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
Pacific Biosciences intends to use the net proceeds from the offering for general corporate purposes, including capital expenditures and working capital. Pacific Biosciences may also use a portion of the net proceeds from the offering to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property, although it has no present commitments or agreements to do so. A shelf registration statement relating to the shares of common stock was previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective on August 18, 2017. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website.
- Simply Wall St.•12 days ago
Is Pacific Biosciences of California Inc (NASDAQ:PACB) A Financially Sound Company?
Investors are always looking for growth in small-cap stocks like Pacific Biosciences of California Inc (NASDAQ:PACB), with a market cap of US$658.4m. However, an important fact which most ignore is:Read More...
- Thomson Reuters StreetEvents•last month
Edited Transcript of PACB earnings conference call or presentation 2-Aug-18 8:30pm GMT
Q2 2018 Pacific Biosciences of California Inc Earnings Call
- Motley Fool•last month
Will This Biotech Stock Join the $1,000 Human Genome Club in Early 2019?
Pacific Biosciences thinks platform upgrades will cut its Sequel machines' DNA sequencing costs 92% by 2019, opening a $2.5 billion market opportunity in 2022.
- Zacks•last month
Pacific Biosciences' Sequel Sees Solid Q2, Competition Rife
Pacific Biosciences (PACB) gains from solid presence in Asia; competition likely to mar results.
- GlobeNewswire•last month
Detailed Research: Economic Perspectives on Allete, Sterling Construction, Illumina, PROS, Altra Industrial Motion, and Pacific Biosciences of California — What Drives Growth in Today's Competitive Landscape
NEW YORK, Aug. 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Allete, ...
- Zacks•2 months ago
Pacific Biosciences (PACB) Loss In Line With Estimates in Q2
Strong performance in Product revenues boosts Pacific Biosciences (PACB) in Q2. Sequel order improves year over year.
- Motley Fool•2 months ago
Pacific Biosciences of California Revenue Up Thanks to More System Installs
Shipments delayed in the first quarter were installed in the second quarter, boosting the gene-sequencing company's revenue.
- Benzinga•2 months ago
The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 2) Akcea Therapeutics Inc (NASDAQ: AKCA ) Arbutus Biopharma Corp ...
- Zacks•2 months ago
Pacific Biosciences of California (PACB) Reports Q2 Loss, Misses Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0.00% and -8.72%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Pacific Biosciences: 2Q Earnings Snapshot
On a per-share basis, the Menlo Park, California-based company said it had a loss of 17 cents. The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- GlobeNewswire•2 months ago
Pacific Biosciences of California, Inc. Announces Second Quarter 2018 Financial Results
MENLO PARK, Calif., Aug. 02, 2018-- Pacific Biosciences of California, Inc. today announced financial results for its second quarter ended June 30, 2018.. Total revenue for the second quarter of 2018 was ...
- ACCESSWIRE•2 months ago
Pacific Biosciences of California, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Pacific Biosciences of California, Inc. (NASDAQ: PACB ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at ...
- GlobeNewswire•2 months ago
Pacific Biosciences Appoints Christian Henry to Board of Directors
Pacific Biosciences of California, Inc. (PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that it has appointed industry veteran Christian Henry to its Board of Directors. Mr. Henry has over 20 years of leadership experience, including over 10 years in executive-level positions at Illumina, Inc. Mr. Henry joined Illumina in 2005 and, during his tenure there, he served in multiple executive roles, including Vice President & Chief Financial Officer, Senior Vice President, Corporate Development, General Manager Life Sciences, and General Manager Genomics Solutions.
- Motley Fool•2 months ago
Here's Why Pacific Biosciences Tumbled 10% Today
Investors are taking a cautious stance ahead of earnings next week and an ongoing trade spat with China.
- Zacks•2 months ago
What's in Store for Pacific Biosciences' (PACB) Q2 Earnings?
Pacific Biosciences' (PACB) flagship Sequel System is likely to drive Q2 results; competition is a headwind.
- Zacks•2 months ago
Moving Average Crossover Alert: Pacific Biosciences of California (PACB)
Pacific Biosciences of California, Inc. (PACB) is looking like an interesting pick from a technical perspective
- GlobeNewswire•2 months ago
Pacific Biosciences of California, Inc. Second Quarter 2018 Financial Results Call
MENLO PARK, Calif., July 23, 2018-- Pacific Biosciences of California, Inc. will hold its quarterly conference call to discuss its Second Quarter 2018 Financial Results on Thursday, August 2, 2018, at ...
